Cytogenix (fka CYGX)

[Paulness]

I really like this part.

Dr. Malcolm Skolnick, CytoGenix President and CEO commented, "This is the next step in our march to make pharmaceutical grade DNA affordable. This is truly a breakthrough technology that changes the economics of cost-sensitive products such as DNA vaccines, antimicrobials and cancer immunotherapy. In the next few years, this technology will drive the development of DNA therapeutics for human and animal application by significantly reducing the costs of finished products